일차 세포 시장, 규모, 점유율, 동향, 산업 분석 보고서 : 유래별, 유형별, 용도별, 최종 사용자별, 지역별 - 예측(2025-2034년)

The primary cells market size is expected to reach USD 4.95 billion by 2034, according to a new study by Polaris Market Research. The report "Primary Cells Market Share, Size, Trends, Industry Analysis Report: By Source, By Type (Animal Source, Human Source), By Application, By End Users, and By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Primary cells are isolated cells that retain the physiological properties of their tissue of origin, making them highly valuable for creating realistic biological models. The growing integration of these cells in personalized medicine, where their ability to replicate patient-specific conditions supports tailored therapeutic strategies, drives the growth opportunities. This trend is reshaping drug discovery and development by improving accuracy in predicting drug responses and reducing the risks of adverse effects. Primary cells are playing a critical role in bridging laboratory research with clinical outcomes as healthcare moves towards more precise and individualized solutions.

The rapid advancement of cell culture technologies has enhanced the utility, stability, and scalability of these cells for research and therapeutic purposes. Modern innovations such as 3D culture systems, advanced co-culture methods, and automation have improved the relevance and reproducibility of studies involving primary cells. These advancements address the traditional limitations of short lifespan and variability and also open new avenues in regenerative medicine, disease modeling, and toxicology testing. As a result, primary cells are becoming essential tools for next-generation biomedical research and therapy development.

Primary Cells Market Report Highlights

In terms of source, the human source segment held a dominant 69.38% revenue share in 2024, owing to its superior physiological relevance for accurately modeling human biological processes.

Based on type, the hepatocytes segment is projected to grow at the fastest CAGR of 12.6%, driven by their critical role in drug metabolism and toxicity testing.

North America led the global market with a 51.46% share in 2024, attributed to its advanced healthcare infrastructure and robust biopharmaceutical R&D sector.

The Asia Pacific market is expected to grow at the highest CAGR of 13.1%, propelled by rising biomedical investments and expanding pharmaceutical manufacturing.

A few global key market players include ALLCells; Axol Bioscience Ltd; Cell Applications, Inc.; Cell Biologics, Inc.; Creative Bioarray; Cureline; Lonza Group, AG; Merck KGaA; Pelobiotech; PromoCell; Sigma-Aldrich; Stem Cell Technologies; Thermo Fisher Scientific; and ZenBio, Inc.

Polaris Market Research has segmented the market report on the basis of source, type, application, end users, and region:

By Source Outlook (Revenue, USD Billion, 2020-2034)

Animal Source

Human Source

By Type Outlook (Revenue, USD Billion, 2020-2034)

Hematopoietic

Hepatocytes

Renal Cells

Gastrointestinal Cells

Skin Cells

Lung Cells

Other Types

By Application Outlook (Revenue, USD Billion, 2020-2034)

ADME Toxicology Testing

Other Applications

By End Users Outlook (Revenue, USD Billion, 2020-2034)

Pharmaceutical & Biotechnology Companies

Research Institutes

By Regional Outlook (Revenue, USD Billion, 2020-2034)

North America

US

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Vietnam

Australia

Rest of Asia Pacific

Latin America

Argentina

Brazil

Mexico

Rest of Latin America

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Rest of Middle East & Africa

Table of Contents

Chapter 1. Introduction

• 1.1 Report Description
  • 1.1.1 Objectives of the Study
  • 1.1.2 Market Scope
  • 1.1.3 Assumptions
• 1.2 Stakeholders

Chapter 2. Executive Summary

Chapter 3. Research Methodology

• 3.1 Overview
  • 3.1.1 Data Mining
• 3.2 Data Sources
  • 3.2.1 Primary Sources
  • 3.2.2 Secondary Sources

Chapter 4. Primary Cells Market Insights

• 4.1 Primary Cells - Industry snapshot
• 4.1 Primary Cells Market Dynamics
  • 4.1.1 Drivers and Opportunities
    • 4.1.1.1 Rising Prevalence of Chronic Diseases and Cancer
    • 4.1.1.2 Advancements in Cell Culture Technologies and Research Tools
    • 4.1.1.2.1 Examples of key financing initiatives, 2024
    • 4.1.1.2.2 Total Global Financings Type by Year
    • 4.1.1.2.3 Widening Global Clinical Landscape
    • 4.1.1.3 Widening Application Portfolio Of Cell Culture Technology
    • 4.1.1.4 Rising Demand For Vaccine Production, Artificial Organs, Media, and Biopharmaceuticals
  • 4.1.2 Restraints and Challenges
    • 4.1.2.1 Scalability Issues
    • 4.1.2.2 Ethical Concerns Pertaining To Animals
• 4.2 Primary Cells Market - Porter's Five Forces
  • 4.2.1 Bargaining Power of Suppliers (Moderate)
  • 4.2.2 Threats of New Entrants: (Low)
  • 4.2.3 Bargaining Power of Buyers (Moderate)
  • 4.2.4 Threat of Substitute (Moderate)
  • 4.2.5 Rivalry among existing firms (High)
• 4.3 Primary Cells Market - PEST Analysis
• 4.4 Covid-19 Impact Analysis & Industry Trends

Chapter 5. Primary Cells Market Assessment by Source

• 5.1 Introduction
• 5.2 Animal Source
• 5.3 Human Source

Chapter 6. Primary Cells Market Assessment by Type

• 6.1 Introduction
• 6.2 Hematopoietic
• 6.3 Hepatocytes
• 6.4 Renal Cells
• 6.5 Gastrointestinal Cells
• 6.6 Skin Cells
• 6.7 Lung Cells
• 6.8 Other Types

Chapter 7. Hepatocytes Market Assessment by Application

• 7.1 Introduction
• 7.2 ADME Toxicology Testing
• 7.3 Other Applications

Chapter 8. Primary Cells Market Assessment by End-Users

• 8.1 Introduction
• 8.2 Pharmaceutical & Biotechnology Companies
• 8.3 Research Institutes

Chapter 9. Primary Cells Market Assessment by Region

• 9.1 Introduction
• 9.2 Primary Cells Market - North America
  • 9.2.1 Primary Cells Market - U.S.
  • 9.2.2 Primary Cells Market - Canada
• 9.3 Primary Cells Market - Europe
  • 9.3.1 Primary Cells Market - Germany
  • 9.3.2 Primary Cells Market - UK
  • 9.3.3 Primary Cells Market - France
  • 9.3.4 Primary Cells Market - Italy
• 9.4 Primary Cells Market - Asia Pacific
  • 9.4.1 Primary Cells Market - China
  • 9.4.2 Primary Cells Market - India
  • 9.4.3 Primary Cells Market - Japan
  • 9.4.4 Primary Cells Market - South Korea
• 9.5 Primary Cells Market - Latin America
  • 9.5.1 Primary Cells Market - Brazil
  • 9.5.2 Primary Cells Market - Mexico
• 9.6 Primary Cells Market - Middle East & Africa

Chapter 10. Competitive Landscape

• 10.1 Product Launch is the Best Adopted Strategy by the Companies
• 10.2 Product Launch
• 10.3 Partnerships/Collaborations/Agreements/Exhibitions

Chapter 11. Company Profiles

• 11.1 Cell Biologics, Inc.
  • 11.1.1 Business Overview
  • 11.1.2 Financial Snapshot
  • 11.1.3 Products and Services
• 11.2 ZenBio, Inc.
  • 11.2.1 Business Overview
  • 11.2.2 Financial Snapshot
  • 11.2.3 Products and Services
• 11.3 Stem Cell Technologies
  • 11.3.1 Business Overview
  • 11.3.2 Financial Snapshot
  • 11.3.3 Products and Services
  • 11.3.4 Recent Developments
• 11.4 Sigma-Aldrich
  • 11.4.1 Business Overview
  • 11.4.2 Financial Snapshot
  • 11.4.3 Products and Services
  • 11.4.4 Recent Developments
• 11.5 Thermo Fisher Scientific
  • 11.5.1 Business Overview
  • 11.5.2 Financial Snapshot
  • 11.5.3 Products and Services
  • 11.5.4 Recent Developments
• 11.6 Cureline
  • 11.6.1 Business Overview
  • 11.6.2 Financial Snapshot
  • 11.6.3 Products and Services
  • 11.6.4 Recent Developments
• 11.7 American Type Culture Collection
  • 11.7.1 Business Overview
  • 11.7.2 Financial Snapshot
  • 11.7.3 Products and Services
  • 11.7.4 Recent Developments
• 11.8 Cell Applications, Inc.
  • 11.8.1 Business Overview
  • 11.8.2 Financial Snapshot
  • 11.8.3 Products and Services
• 11.9 Pelobiotech
  • 11.9.1 Business Overview
  • 11.9.2 Financial Snapshot
  • 11.9.3 Products and Services
  • 11.9.4 Recent Developments
• 11.10 Merck KGaA
  • 11.10.1 Business Overview
  • 11.10.2 Financial Snapshot
  • 11.10.3 Products and Services
  • 11.10.4 Recent Developments
• 11.11 Axol Bioscience Ltd
  • 11.11.1 Business Overview
  • 11.11.2 Financial Snapshot
  • 11.11.3 Products and Services
  • 11.11.4 Recent Developments
• 11.12 PromoCell
  • 11.12.1 Business Overview
  • 11.12.2 Financial Snapshot
  • 11.12.3 Products and Services
  • 11.12.4 Recent Developments
• 11.13 ALLCells
  • 11.13.1 Business Overview
  • 11.13.2 Financial Snapshot
  • 11.13.3 Products and Services
  • 11.13.4 Recent Developments
• 11.14 Lonza Group, AG
  • 11.14.1 Business Overview
  • 11.14.2 Financial Snapshot
  • 11.14.3 Products and Services
  • 11.14.4 Recent Developments
• 11.15 Creative Bioarray
  • 11.15.1 Business Overview
  • 11.15.2 Financial Snapshot
  • 11.15.3 Products and Services